Shopping Cart 0
Cart Subtotal
AED 0

N4 Pharma Plc (N4P) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

N4 Pharma Plc (N4 Pharma), formerly Onzima Ventures Plc is a pharmaceutical company that reformulates vaccines and drugs. The company provides generic products such as sartans, sildenafil, and aprepitant. It also provides single dose hepatitis B vaccines. N4 Pharma's sildenafil is used to treat erectile dysfunctions. The company's sartans that includes losartan and valsartan is commonly used for the treatment of hypertension and also identifies established drugs to improve through its reformulation techniques. The company also conducts research and development to generate the clinical proof of concept data for reformulations. It also develops novel products for licensing to pharmaceutical and biotechnology partners. N4 Pharma is headquartered in Derby, the UK.

N4 Pharma Plc (N4P)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

N4 Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 10

Equity Offering 10

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 10

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 11

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 12

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 13

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 14

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 15

N4 Pharma Raises USD0.2 Million in Private Placement of Shares up on Exercise of Warrants 16

N4 Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 17

N4 Pharma Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 18

N4 Pharma Raises Funds through Private Placement of Shares up on Exercise of Warrants 19

Acquisition 20

Onzima Ventures to Acquire Remaining 51% Stake in N4 Pharma in Reverse Takeover Transaction 20

Onzima Ventures Acquires 49% Stake in N4 Pharma 21

N4 Pharma Plc-Key Competitors 22

N4 Pharma Plc-Key Employees 23

N4 Pharma Plc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Sep 20, 2018: N4 Pharma: Interim Results of 30 June 2018 25

Sep 25, 2017: N4 Pharma: Interim Results 28

Government and Public Interest 40

Feb 02, 2018: N4 Pharma secures Innovate UK grant to co-fund collaborative project with MedImmune UK 40

Feb 02, 2018: N4 Pharma: Award of Grant and Collaboration with MedImmune UK 41

Product News 42

Nov 08, 2017: N4 Pharma: Results of latest nuvec pre-clinical study 42

Sep 24, 2018: N4 Pharma: Acceptance of Nuvec on EUNCL Charecterisation programme 43

Jun 30, 2017: N4 Pharma: Update on toxicity testing of nuvec particles 44

Jun 18, 2018: N4 Pharma: Update on Nuvec 45

Other Significant Developments 46

Sep 20, 2018: N4 Pharma: Strategic review 46

Mar 08, 2018: N4 Pharma: Nuvec Update 48

Jul 27, 2017: N4 Pharma provides Update on Sildenafil clinical plans 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

N4 Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

N4 Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

N4 Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 8

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 10

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 11

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 12

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 13

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 14

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 15

N4 Pharma Raises USD0.2 Million in Private Placement of Shares up on Exercise of Warrants 16

N4 Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 17

N4 Pharma Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 18

N4 Pharma Raises Funds through Private Placement of Shares up on Exercise of Warrants 19

Onzima Ventures to Acquire Remaining 51% Stake in N4 Pharma in Reverse Takeover Transaction 20

Onzima Ventures Acquires 49% Stake in N4 Pharma 21

N4 Pharma Plc, Key Competitors 22

N4 Pharma Plc, Key Employees 23

N4 Pharma Plc, Subsidiaries 24

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

N4 Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

N4 Pharma Plc (N4 Pharma), formerly Onzima Ventures Plc is a pharmaceutical company that reformulates vaccines and drugs. The company provides generic products such as sartans, sildenafil, and aprepitant. It also provides single dose hepatitis B vaccines. N4 Pharma's sildenafil is used to treat erectile dysfunctions. The company's sartans that includes losartan and valsartan is commonly used for the treatment of hypertension and also identifies established drugs to improve through its reformulation techniques. The company also conducts research and development to generate the clinical proof of concept data for reformulations. It also develops novel products for licensing to pharmaceutical and biotechnology partners. N4 Pharma is headquartered in Derby, the UK.

N4 Pharma Plc (N4P)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

N4 Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deal Details 10

Equity Offering 10

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 10

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 11

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 12

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 13

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 14

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 15

N4 Pharma Raises USD0.2 Million in Private Placement of Shares up on Exercise of Warrants 16

N4 Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 17

N4 Pharma Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 18

N4 Pharma Raises Funds through Private Placement of Shares up on Exercise of Warrants 19

Acquisition 20

Onzima Ventures to Acquire Remaining 51% Stake in N4 Pharma in Reverse Takeover Transaction 20

Onzima Ventures Acquires 49% Stake in N4 Pharma 21

N4 Pharma Plc-Key Competitors 22

N4 Pharma Plc-Key Employees 23

N4 Pharma Plc-Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

Sep 20, 2018: N4 Pharma: Interim Results of 30 June 2018 25

Sep 25, 2017: N4 Pharma: Interim Results 28

Government and Public Interest 40

Feb 02, 2018: N4 Pharma secures Innovate UK grant to co-fund collaborative project with MedImmune UK 40

Feb 02, 2018: N4 Pharma: Award of Grant and Collaboration with MedImmune UK 41

Product News 42

Nov 08, 2017: N4 Pharma: Results of latest nuvec pre-clinical study 42

Sep 24, 2018: N4 Pharma: Acceptance of Nuvec on EUNCL Charecterisation programme 43

Jun 30, 2017: N4 Pharma: Update on toxicity testing of nuvec particles 44

Jun 18, 2018: N4 Pharma: Update on Nuvec 45

Other Significant Developments 46

Sep 20, 2018: N4 Pharma: Strategic review 46

Mar 08, 2018: N4 Pharma: Nuvec Update 48

Jul 27, 2017: N4 Pharma provides Update on Sildenafil clinical plans 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

N4 Pharma Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

N4 Pharma Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

N4 Pharma Plc, Deals By Therapy Area, 2012 to YTD 2018 8

N4 Pharma Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 10

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 11

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 12

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 13

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 14

N4 Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 15

N4 Pharma Raises USD0.2 Million in Private Placement of Shares up on Exercise of Warrants 16

N4 Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 17

N4 Pharma Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 18

N4 Pharma Raises Funds through Private Placement of Shares up on Exercise of Warrants 19

Onzima Ventures to Acquire Remaining 51% Stake in N4 Pharma in Reverse Takeover Transaction 20

Onzima Ventures Acquires 49% Stake in N4 Pharma 21

N4 Pharma Plc, Key Competitors 22

N4 Pharma Plc, Key Employees 23

N4 Pharma Plc, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

N4 Pharma Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.